A study of 44 cases of recurrent or metastatic head and neck cancer treated with nivolumab

Kawase, Katsushige; Koshizuka, Keiichi; Yoneda, Riyo; Yamasaki, Kazuki; Yonekura, Syuji; Hanazawa, Toyoyuki

doi:10.5981/jjhnc.47.284

Cited by 3 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HRs for OS were reported in 11 studies comprising 710 patients 5,13,14,17–21,23–25 and ranged from 0.86 to 5.04. The pooled analysis results are shown in Figure 3A.…”

Section: Resultsmentioning

confidence: 99%

“…Newer data was used when the same outcome data was presented in both studies. Of these 14 studies, nine, 13–15,17,18,21,23–25 all of which were studies from Japan, investigated patients treated with nivolumab. Only two studies 17,21 were multicenter cohort studies, whereas the remaining twelve 5,13–16,18–20,22–25 were single‐center cohort studies.…”

Section: Resultsmentioning

confidence: 99%

“…HRs and 95% CIs were preferentially extracted from multivariate analyses; if unavailable, HRs were extracted from univariate analyses. Survival data were extracted from Kaplan–Meier curves in three studies, 22,24,25 and HRs were estimated using the method proposed by Tierney et al 27 The study by Ueki et al 13 did not show HRs, and the HR for this study was estimated from the 1‐year survival rate. The HRs and ORs for the study by Valero et al 5 were estimated from published raw data.…”

Section: Methodsmentioning

confidence: 99%

“…Moreover, meta‐analyses of the prognostic impact of NLR in patients treated with ICIs have been published for some types of cancers 9–12 . However, only small‐scale cohort studies with inconsistent results have reported the association between the NLR and ICIs in HNSCC 5,13–25 …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis

et al. 2022

View full text Add to dashboard Cite

We investigated the prognostic impact of the neutrophil‐to‐lymphocyte ratio (NLR) in patients with head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors (ICIs). We systematically searched electronic databases and identified articles reporting an association between NLR and treatment results in patients with HNSCC treated with ICIs. Hazard ratios (HRs) for overall survival (OS) and progression‐free survival (PFS) and odds ratios (ORs) for response and disease control were extracted. Pooled HRs and ORs were estimated using random‐effects models. Fourteen studies involving 929 patients were included. A higher NLR was associated with poor OS (HR 2.03, 95% confidence interval [CI] 1.50–2.74), PFS (HR 2.15, 95% CI 1.44–3.21), response (OR 0.49, 95% CI 0.26–0.93), and disease control (OR 0.30, 95% CI 0.12–0.74). The NLR predicts treatment results with ICIs in patients with HNSCC.

show abstract

“…The HRs for OS were reported in 11 studies comprising 710 patients 5,13,14,17–21,23–25 and ranged from 0.86 to 5.04. The pooled analysis results are shown in Figure 3A.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors

Kang,

Liu,

Yuan

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors

Kang

Liu

Yuan

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Tumor immunotherapy has recently emerged as a crucial focal point in oncology treatment research. Among tumor immunotherapy approaches, tumor immune checkpoint inhibitors (ICIs) have attracted substantial attention in clinical research. However, this treatment modality has benefitted only a limited number of patients. We conducted a meta-analysis of various biomarkers to decipher their prognostic implications in patients with head and neck squamous cell carcinoma (HNSCC) who are treated with ICIs and thus identify predictive markers with practical clinical relevance. Methods: A systematic search of electronic databases was conducted to identify clinical studies that examined the correlation between biomarkers and treatment outcomes in the HNSCC patients. The included articles were screened and analyzed to extract data regarding overall survival (OS), progression-free survival (PFS). Results: The relationship between the biomarkers included in the summary and prognosis was as follows: HPV positivity was associated with improved OS (HR = 0.76, 95% CI = 0.58–1.99), PFS (HR = 1.16, 95% CI = 0.81–1.67), and response (OR = 1.67, 95% CI = 1.37–2.99). PD-L1 positivity was associated with OS (HR = 0.71, 95% CI = 0.59–0.85), PFS (HR = 0.56 95% CI = 0.43–0.73), and response (OR = 2.16, 95% CI = 1.51–3.10). Neither HPV positivity nor PD-L1 positivity was associated with DCR. The following markers were collected for OS and PFS data and were associated with longer OS: lower Glasgow prognostic score (GPS/mGPS) grading, lower PS grading, high body mass index (BMI), low neutrophil-to-lymphocyte ratio (NLR), low platelet-to-lymphocyte ratio (PLR), high albumin (Alb), low lactate dehydrogenase (LDH). Factors associated with better PFS were lower GPS/mGPS grading, lower PS grading, high BMI, low NLR, high absolute lymphocyte count, and low LDH. Hyperprogressive disease was associated with worse OS and PFS. Fewer clinical studies have been completed on the tumor microenvironment and hypoxia, microsatellite instability/DNA mismatch repair, and microbiome and systematic analysis is difficult. Conclusions: In our meta-analysis, different immune checkpoint factors were associated with different prognoses in HNSCC patients receiving immunotherapy. HPV, PD-L1, BMI, Alb, HPD, PS, GPS/mGPS, LDH, NLR, and PLR predicted the ICI outcome in HNSCC patients.

show abstract

A study of 44 cases of recurrent or metastatic head and neck cancer treated with nivolumab

Cited by 3 publications

References 10 publications

Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis

Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors

Contact Info

Product

Resources

About